Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C+BuCy conditioning regimen for high-risk pediatric acute leukemia before hematopoietic stem cell transplantation
ChiCTR2000032322Phase 4Not yet recruiting
- Sponsor
- Children's Hospital of Soochow University
- Start
- Dec 2019
- Modality
- Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cladribine, cytarabine, filgrastim, lomustine, busulfan and 1 more in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Children's Hospital of Soochow University. Primary endpoints: 2-year overall survival, 2-year progression-free survival and 1 more. Planned start Dec 2019; status: not yet recruiting.
02
Drugs
cladribinecytarabinefilgrastimlomustinebusulfan
03
Conditions
acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on ChiCTR2000032322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000032322.